EDAP Announces 2005 Revenue Estimates
January 11 2006 - 4:30PM
PR Newswire (US)
Strong Cash Position Maintained Increased Q4 Performance; Strong
Backlog Entering 2006 LYON, France, Jan. 11 /PRNewswire-FirstCall/
-- EDAP TMS S.A. (NASDAQ:EDAP), ahead of the release of its 2005
annual results scheduled for mid-March 2006, today confirmed 2005
Company revenues in line with management expectations and a strong
cash position at year end. The Company reported unaudited 2005
fourth quarter sales revenues estimated in excess of EUR 6 million
compared to EUR 5.8 million in 2004, the strongest revenue quarter
in more than two years. Both revenue figures are before the effect
of performance warrants. Total unaudited sales revenues for the
2005 year are estimated at EUR 21 million, in line with the
management's expectations. These results include a successful shift
of the business from one-time device sales toward recurring
treatment procedure sales and growth in the company's end markets.
Group cash position at year end strengthened to more than EUR 8
million versus EUR 7.5 million at September 2005, reflecting the
Company's revenue growth and cash management policy. Hugues de
Bantel, CEO of EDAP TMS, commented: "We are very pleased with our
strong fourth quarter performance, as predicted in our third
quarter release. This performance confirms the growth trends in our
mobile per procedure services and sales of Ablatherm-HIFU devices
during the quarter. These results reflect continued growing
interest in HIFU treatment and our HIFU business model's success.
The quarter's performance includes units placed in view of
expanding our Ablatherm-HIFU cost-per-procedure business. Our
marketing efforts, plus growing clinical credibility and
reimbursement approval in the United Kingdom during 2005, are being
rewarded with clear growth in our HIFU business, and we anticipate
pursuing this outstanding marketing and awareness strategy by using
our cash carefully. I am also very pleased to confirm an increased
backlog of Ablatherm-HIFU and lithotripter device sales entering
2006." With more than 96 sites using Ablatherm-HIFU worldwide, 62
on a mobile basis, and an estimated 9,000 treatments performed as
of December 31, 2005, EDAP is extending its already established
leadership in the HIFU minimally invasive treatment of localized
prostate cancer. Approximately 500,000 men are diagnosed with
prostate cancer in western countries each year. Men diagnosed with
prostate cancer will look for an appropriate treatment with the
lowest side effects, thereby preserving their best quality of life.
EDAP, with its Ablatherm-HIFU, is responding to this growing
sensitivity, awareness and concern from patients suffering from
localized prostate cancer. Investor Communications Management will
conduct investor meetings in the United States January 16 to 27,
2006. Meetings will be held in Portland, Seattle, San Francisco,
Dallas, Minneapolis, Boston, New York and Atlanta. Investors
wishing to schedule an appointment should contact Matt Kreps at
Halliburton Investor Relations at 972-458-8000 or . Warrants Impact
Please note that these 2005 expectations and figures are not
audited and are given without the warrant impact. 2005 results will
include a non-cash charge, booked in deduction of UDS division
sales revenues and HIFU division sales revenues in connection with
warrants issued to HealthTronics, Inc., the Company's U.S.
marketing partner, under its distribution agreement with
HealthTronics. The non-cash charge that will be recorded in 2005
relates to a series of warrants that vested in 2005 by meeting
performance milestones, in accordance with the terms of the
agreement. Additional details on the computation of this non-cash
charge will be developed further in the Company's release of 2005
Full Year and Fourth Quarter results in March 2006. For further
details on warrants impact, please refer to the Company's 2004 Form
20-F filed with the SEC. About EDAP TMS S.A. EDAP TMS S.A. develops
and markets Ablatherm-HIFU, the most advanced and clinically proven
choice for High Intensity Focused Ultrasound (HIFU) treatment of
localized prostate cancer. HIFU treatment is shown to be a
minimally invasive and effective treatment option with a low
occurrence of side effects. The company is also developing this
technology for the treatment of certain other types of tumors. EDAP
TMS S.A. also produces and commercializes medical equipment for
treatment of urinary tract stones using Extra-corporeal Shockwave
Lithotripsy (ESWL). For more information on the Company, contact
the Investor Relations Dept. by phone at +33 (0)4 78 26 40 46 or
see the Company's Web site at: http://www.edap-tms.com/ . This
press release contains, in addition to historical information,
forward-looking statements that involve risks and uncertainties.
These include statements regarding the Company's growth and
expansion plans. Such statements are based on management's current
expectations and are subject to a number of uncertainties and risks
that could cause actual results to differ materially from those
described in the forward-looking statements. Factors that may cause
such a difference include, but are not limited to, those described
in the Company's filings with the Securities and Exchange
Commission. CONTACT: EDAP TMS S.A. Hugues de Bantel - Philippe
Chauveau Blandine Confort +33 4 78 26 40 46 Halliburton Investor
Relations Matt Kreps - Geralyn DeBusk +1 972 458 8000 DATASOURCE:
EDAP TMS S.A. CONTACT: Hugues de Bantel, or Philippe Chauveau, or
Blandine Confort, all of EDAP TMS S.A., +33-4-78-26-40-46; or Matt
Kreps or Geralyn DeBusk, both of Halliburton Investor Relations,
+1-972-458-8000, for EDAP TMS S.A. Web site:
http://www.edap-tms.com/
Copyright
EDAP TMS (NASDAQ:EDAP)
Historical Stock Chart
From Jun 2024 to Jul 2024
EDAP TMS (NASDAQ:EDAP)
Historical Stock Chart
From Jul 2023 to Jul 2024